Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2025 23:51 ET | Source: InnoCare Pharma

Latest Data of InnoCare's Zurletrectinib Orally Presented at SIOP 2025

Zurletrectinib demonstrated well-tolerated safety and promising antitumor activity in pediatric/adolescent patients with NTRK/ROS1-altered solid tumors.